title: CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population.
abstract: BACKGROUND
  This study was aimed to explore the clinical characteristics and prognoses of acute myeloid leukemia (AML) patients with CEBPA mutations.
  
  
  METHODS
  Three hundred and forty-five patients with de novo AML were retrospectively analyzed with regard to CEBPA mutations, clinical characteristics, therapeutic responses, and long-term outcomes.
  
  
  RESULTS
  CEBPA mutations were detected in 59 patients (17.10%), with 47 cases harboring double mutations and 12 cases harboring single mutations. In those with a normal karyotype (NK), 44 cases (25.29%) were detected with CEBPA mutations. The following characteristics were observed in CEBPA-mutated patients: most (66.10%) of them were M1 or M2; they presented with higher peripheral white blood cell counts (23.71 [12.6, 60.02] ×10(9)/L versus 7.34 [2.38, 26.63] ×10(9)/L; u=4.944, P<0.001) and higher hemoglobin levels (89.64±23.05 g/L versus 75.65±23.65 g/L; t=4.156, P<0.001) than those observed in patients without the mutation; and the expression of CD7 and HLA-DR was higher, whereas that of CD34 and CD56 was lower in patients with the mutation than in those without the mutation. Compared with those without the mutation, patients with CEBPA mutations had a superior complete remission rate (75.0% versus 56.54%; χ (2)=6.185, P=0.013) and superior overall survival (P=0.034).
  
  
  CONCLUSIONS
  The frequency of CEBPA mutations may be higher in Chinese patients with AML than has been reported in populations of western countries, and the presence of CEBPA mutations is an indication of favorable prognoses for these patients.
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: Long
authors.initials: L
authors.lastname: Su
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: SuJun
authors.initials: S
authors.lastname: Gao
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: XiaoLiang
authors.initials: X
authors.lastname: Liu
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: YeHui
authors.initials: Y
authors.lastname: Tan
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: Lu
authors.initials: L
authors.lastname: Wang
authors.affiliation: Cancer Center, The First Hospital, Jilin University, Changchun, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
keywords: CEBPA mutations; acute myeloid leukemia; complete remission; immunophenotype; long-term prognoses